OptiNose: Funding, Investors & Team (Sep 2026)
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who get ENT and allergy treatments. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, is a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if authorized, chronic rhinosinusitis without nasal polyps. It uses our exclusive Exhalation Delivery System (EDS) (also known as chronic sinusitis) The US Food and Drug Administration (FDA) approved XHANCE in September 2017 for the treatment of nasal polyps in individuals who were 18 years of age or older. In April 2018, XHANCE became readily accessible through commercial channels.
OptiNose has raised $105M across 2 funding rounds on record, the most recent an undisclosed round of $55.0M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OptiNose Company Profile and Key Stats
Latest funding round on record: May 2024.
OptiNose Funding Rounds
OptiNose raised $50.0M in an undisclosed round announced in Nov 2022.
1.5 years later, an undisclosed round of $55.0M was announced in May 2024.
OptiNose Founders and Leadership Team
Contact details for the OptiNose team: 1 of 1 has an email address on file.
Start 14-day free trial →OptiNose Funding Compared to Other Biotechnology Startups
OptiNose's latest round of $55.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OptiNose in Biotechnology and Oslo
Companies Similar to OptiNose
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on…
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These…
OptiNose Funding FAQs
What does OptiNose do?
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who get ENT and allergy treatments. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, is a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if authorized, chronic rhinosinusitis without nasal polyps. It uses our exclusive Exhalation Delivery System (EDS) (also known as chronic sinusitis) The US Food and Drug Administration (FDA) approved XHANCE in September 2017 for the treatment of nasal polyps in individuals who were 18 years of age or older. In April 2018, XHANCE became readily accessible through commercial channels.
How much funding has OptiNose raised?
OptiNose has raised $105M across 2 rounds on record. The most recent is an undisclosed round of $55.0M announced in May 2024.
When did OptiNose last raise funding?
OptiNose's most recent funding round on record is an undisclosed round of $55.0M, announced in May 2024.
Who founded OptiNose?
FundedIQ lists Per Djupesland (Founder) at OptiNose.
Where is OptiNose headquartered?
OptiNose is based in Oslo, Norway.
How many employees does OptiNose have?
OptiNose is in the 101-250 employee band.
How does OptiNose's funding compare to other Biotechnology startups?
OptiNose's latest round of $55.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's OptiNose Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OptiNose is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.